Biotechnology, Pharmaceutical and Life Science Reports and Courses

Main Pages

Best Selling Products

BioNewsCast Press Release Distribution Service

Vaccine Technology 2009 Conference

Veterinary Diagnostics Markets

Practical Guide to Finding Partners in Pharma & Biotech, 2nd edition

Royalty Financing Agreements in Pharma, Biotech and Diagnostics

New Products

Attention Deficit Hyperactivity Disorder: Diagnosis and Treatment

Bioinformatics Market Potential

Biotechnology in the European Union; Trends, Investing & Country Profiles

China Pharmaceutical Industry: Analysis and Market Trends

European Generic Drug Market Potential

Global Biotechnology Markets Trends

Strategic Alliances in World Pharma and Biotech Markets

Understanding China's Chemical Industry

Understanding Genomics and Global Health Impacts

Understanding Pharmacogenomics

BioPortfolio | Datamonitor Reports | Stakeholder Opinions: Cancer Cachexia - Higher profile needed to unlock market potential of neglected syndrome

Stakeholder Opinions: Cancer Cachexia - Higher profile needed to unlock market potential of neglected syndrome

Cancer cachexia is a muscle and fat wasting syndrome that affects the majority of incurable cancer patients and adversely impacts treatment outcomes, survival and quality of life. Current treatment options for cancer cachexia are limited. The lack of a universal objective definition and the low profile of the condition among oncologists have restricted advances in treatment.

Cancer cachexia overview, including definition of the condition, pathophysiology and patient population estimates in the seven major markets

Treatment of cancer cachexia, including discussion of drug therapies currently available and unmet needs

Examination of cancer cachexia pipeline activity including profiles of late-phase pipeline drugs and clinical trial design discussion

Stakeholder opinions based on qualitative interviews with opinion leaders in the field of cancer cachexia

The lack of effective drug therapy is the biggest unmet need in cancer cachexia. Megestrol acetate is used off-label but does not increase lean body mass. Corticosteroids are also used off-label, but their side effect profile restricts use to a short-term basis. A multimodal approach to therapy may be the best way of improving treatment outcomes.

Several different types of clinician are involved in the management of cancer cachexia, but oncologists have the greatest influence. Drug companies should raise awareness of cachexia among oncologists to improve treatment and build a market. This may also help to promote a more universal multidisciplinary team approach to cancer cachexia care.

Developers of cancer cachexia drugs face several large hurdles. The lack of a universal, objective definition of cancer cachexia means that there is uncertainty over which patients to recruit for clinical trials. Furthermore, controversy surrounds clinical trial endpointsit is unclear which endpoints should be use and how to measure a response.

Assess the size of the cancer cachexia population (both overall and for specific tumor types) in the seven major markets

Understand unmet needs in cancer cachexia and the challenges facing developers of drugs for cancer cachexia

Identify products in clinical development for cancer cachexia. Consider, assess and react to opportunities and risks influencing their potential

Publication: 39814
Library Code: DMHC2472
Type: Report
Format: PDF & SlidePack
Pages: 104

Table of Contents
Price: $3,800.00 / €2,539.92

BioPortfolio uses RBS Worldpay Secure Server for credit card transactions